Pinos Elisabet de los - 19 Jan 2023 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Julie Feder, as Attorney-in-Fact
Issuer symbol
AURA
Transactions as of
19 Jan 2023
Net transactions value
$0
Form type
4
Filing time
23 Jan 2023, 17:35:53 UTC
Previous filing
02 Nov 2022
Next filing
01 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +121,875 +178% $0.000000 190,526 19 Jan 2023 Direct F1
holding AURA Common Stock 131,412 19 Jan 2023 By EdIP Revocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award +187,500 187,500 19 Jan 2023 Common Stock 187,500 $10.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
F2 The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.
F3 The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments.

Remarks:

President and Chief Executive Officer